Q-omics provides the consensus-scored H2BU1 profile across patient tissues and cancer cell-line models. H2BU1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, H2BU1 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, H2BU1 RNA expression shows 16,962 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, BLCA, and UVM as cancer lineages where H2BU1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2BU1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2BU1 survival associations across molecular data types. H2BU1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2BU1 RNA expression–survival associations across cancer types. High H2BU1 expression shows unfavorable associations in KIRP, COAD, UVM and LIHC, but favorable associations in BRCA and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for H2BU1 RNA expression.
This table summarizes H2BU1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for H2BU1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2BU1 shows higher tumor expression in BLCA, COAD, BRCA, THCA, LIHC and KIRC. The BLCA box plot shows higher H2BU1 RNA expression in tumor versus normal tissue (log2 FC = +1.991, t-test p < 0.001).
This table shows molecular features associated with H2BU1 in patient tissues and cancer cell lines. In patient samples, H2BU1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, H2BU1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
